Plasma Complement factor H in Alzheimer's Disease.

Michael A. Williams, David Haughton, Michael Stevenson, David Craig, A. Peter Passmore, Giuliana Silvestri

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Biomarkers for Alzheimer's disease (AD) should meet several criteria, including simplicity of testing. Inappropriate activation of the complement cascade has been implicated in the pathogenesis of AD. Complement factor H (CFH) is a regulator of the cascade, but studies on plasma CFH levels in AD have provided mixed results. This study compared plasma CFH levels in 317 AD cases with 254 controls using an immunodiffusion assay. The sample had an 80% power to detect a difference of 23 mg/L between cases and controls, but no difference was evident. Plasma CFH may not be a suitable biomarker for AD.
Original languageEnglish
Pages (from-to)369-372
Number of pages4
JournalJournal of Alzheimer's disease : JAD
Volume45
Issue number2
Early online date07 Jan 2015
DOIs
Publication statusPublished - 2015

Fingerprint

Complement Factor H
Alzheimer Disease
Biomarkers
Complement Activation
Immunodiffusion

Cite this

Williams, Michael A. ; Haughton, David ; Stevenson, Michael ; Craig, David ; Passmore, A. Peter ; Silvestri, Giuliana. / Plasma Complement factor H in Alzheimer's Disease. In: Journal of Alzheimer's disease : JAD. 2015 ; Vol. 45, No. 2. pp. 369-372.
@article{4cad2f42cfd44bb4a0df19b39c134a4c,
title = "Plasma Complement factor H in Alzheimer's Disease.",
abstract = "Biomarkers for Alzheimer's disease (AD) should meet several criteria, including simplicity of testing. Inappropriate activation of the complement cascade has been implicated in the pathogenesis of AD. Complement factor H (CFH) is a regulator of the cascade, but studies on plasma CFH levels in AD have provided mixed results. This study compared plasma CFH levels in 317 AD cases with 254 controls using an immunodiffusion assay. The sample had an 80{\%} power to detect a difference of 23 mg/L between cases and controls, but no difference was evident. Plasma CFH may not be a suitable biomarker for AD.",
author = "Williams, {Michael A.} and David Haughton and Michael Stevenson and David Craig and Passmore, {A. Peter} and Giuliana Silvestri",
year = "2015",
doi = "10.3233/JAD-142742",
language = "English",
volume = "45",
pages = "369--372",
journal = "Journal of Alzheimer's disease : JAD",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

Plasma Complement factor H in Alzheimer's Disease. / Williams, Michael A.; Haughton, David; Stevenson, Michael; Craig, David; Passmore, A. Peter; Silvestri, Giuliana.

In: Journal of Alzheimer's disease : JAD, Vol. 45, No. 2, 2015, p. 369-372.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Plasma Complement factor H in Alzheimer's Disease.

AU - Williams, Michael A.

AU - Haughton, David

AU - Stevenson, Michael

AU - Craig, David

AU - Passmore, A. Peter

AU - Silvestri, Giuliana

PY - 2015

Y1 - 2015

N2 - Biomarkers for Alzheimer's disease (AD) should meet several criteria, including simplicity of testing. Inappropriate activation of the complement cascade has been implicated in the pathogenesis of AD. Complement factor H (CFH) is a regulator of the cascade, but studies on plasma CFH levels in AD have provided mixed results. This study compared plasma CFH levels in 317 AD cases with 254 controls using an immunodiffusion assay. The sample had an 80% power to detect a difference of 23 mg/L between cases and controls, but no difference was evident. Plasma CFH may not be a suitable biomarker for AD.

AB - Biomarkers for Alzheimer's disease (AD) should meet several criteria, including simplicity of testing. Inappropriate activation of the complement cascade has been implicated in the pathogenesis of AD. Complement factor H (CFH) is a regulator of the cascade, but studies on plasma CFH levels in AD have provided mixed results. This study compared plasma CFH levels in 317 AD cases with 254 controls using an immunodiffusion assay. The sample had an 80% power to detect a difference of 23 mg/L between cases and controls, but no difference was evident. Plasma CFH may not be a suitable biomarker for AD.

U2 - 10.3233/JAD-142742

DO - 10.3233/JAD-142742

M3 - Article

VL - 45

SP - 369

EP - 372

JO - Journal of Alzheimer's disease : JAD

JF - Journal of Alzheimer's disease : JAD

SN - 1387-2877

IS - 2

ER -